BOSTON and BRUSSELS, June 30, 2011 /PRNewswire/ -- UCB and Harvard University officially launched their innovative Research Alliance during a signing ceremony that took place in Boston last night in the presence of his Royal Highness Prince Philippe of Belgium.
The Alliance creates a unique drug discovery bridge between industry and academia, with Harvard scientists continuing their research that holds potential for the development of new therapeutic modalities in clinical medicine. The strategy underlying the collaborative alliance is to advance ongoing Harvard research projects along the drug development pathway.
"Harvard's world-class academic research is an excellent fit with UCB's world-class antibody research and central nervous system (CNS) pharmacology," said Ismail Kola, President of UCB NewMedicines. "Both parties will learn from each other through the collaboration and a two-way exchange of ideas. Harvard will benefit from UCB's strengths and industry experience in drug discovery and development; while Harvard's exceptional research will complement UCB's internal expertise.''
The first research project funded under the Harvard-UCB alliance is a collaboration with Professor Gokhan S. Hotamisligil, M.D., Ph.D., Chair, Department of Genetics and Complex Diseases, Harvard School of Public Health, to generate and develop antibodies against an exciting target with potential application in a range of diseases including diabetes and metabolic disorders.
"We couldn't be more pleased about entering into this innovative collaboration with UCB, which joins together leaders in academia and industry to advance pioneering research from the lab to the clinic," said Isaac T. Kohlberg, Harvard's Chief Technology Development Officer and head of its Office of Technology Development. "In furtherance of our mis